Clinical Trial

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Single arm phase II study of Chlorambucil in combination with subcutaneous Rituximab followed by maintenance therapy with subcutaneous Rituximab in patients with histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT type arisen at any extranodal site, either de novo, or relapsed following local therapy (including surgery, radiotherapy and antibiotics for H. pylori-positive gastric lymphoma).
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2013-03-08; most recent amendment 2026-01-14.
Status change: Recruiting → Active, Not Recruiting 2016-07-26
Status change: Not Yet Recruiting → Recruiting 2014-10-03
Trial Details
NCT Number NCT01808599
Lead Sponsor International Extranodal Lymphoma Study Group (IELSG)
Conditions MALT Lymphoma
Enrollment 112 participants
Start Date 2013-12
Primary Completion 2016-03 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-01-15